The emerging role of incretins and twincretins

Nature Reviews Endocrinology, Published online: 06 December 2021; doi:10.1038/s41574-021-00607-wIn 2021, clinical trials reported the promising effects of incretins and a new class of dual glucagon-like peptide 1–glucose-dependent insulinotropic peptide receptor agonists in preventing and treating type 2 diabetes mellitus and obesity. These ‘twincretins’ will transform the prevention of obesity and type 2 diabetes mellitus and the care of people with these conditions.
Source: Nature Reviews Endocrinology - Category: Endocrinology Authors: Source Type: research